Global Migraine Headache Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Migraine Headache Drugs Market Research Report 2024
Migraine treatment usually is with over-the-counter (OTC) migraine medication or prescription drugs.
Migraines, this type of headache often involves only one side of the head, but in some cases, patients may have pain bilaterally or on both sides. Migraine headache is a result of specific changes within the brain. It causes severe head pain that is often accompanied by sensitivity to light, sound, or smells.
According to Mr Accuracy reports’s new survey, global Migraine Headache Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Migraine Headache Drugs market research.
Key companies engaged in the Migraine Headache Drugs industry include Pfizer, Novartis, Johnson & Johnson, GSK, Merck, Eli Lilly, Teva, AstraZeneca and Sun Pharma, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Migraine Headache Drugs were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Migraine Headache Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Migraine Headache Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Novartis
Johnson & Johnson
GSK
Merck
Eli Lilly
Teva
AstraZeneca
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Mylan
Bayer
Amneal Pharmaceuticals
Apotex
Ajanta Pharma
Allergan
Segment by Type
Almotriptan
Eletriptan
Sumatriptan
Rizatriptan
Zolmitriptan
Naratriptan
Frovatriptan
Others
Acute Migraine
Common Migraine
Classic Migraine
Chronic Migraine
Other Migraines
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Migraine Headache Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Migraines, this type of headache often involves only one side of the head, but in some cases, patients may have pain bilaterally or on both sides. Migraine headache is a result of specific changes within the brain. It causes severe head pain that is often accompanied by sensitivity to light, sound, or smells.
According to Mr Accuracy reports’s new survey, global Migraine Headache Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Migraine Headache Drugs market research.
Key companies engaged in the Migraine Headache Drugs industry include Pfizer, Novartis, Johnson & Johnson, GSK, Merck, Eli Lilly, Teva, AstraZeneca and Sun Pharma, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % value of Migraine Headache Drugs were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Migraine Headache Drugs market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Migraine Headache Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Novartis
Johnson & Johnson
GSK
Merck
Eli Lilly
Teva
AstraZeneca
Sun Pharma
Grunenthal
Endo Pharmaceuticals
Mylan
Bayer
Amneal Pharmaceuticals
Apotex
Ajanta Pharma
Allergan
Segment by Type
Almotriptan
Eletriptan
Sumatriptan
Rizatriptan
Zolmitriptan
Naratriptan
Frovatriptan
Others
Segment by Application
Acute Migraine
Common Migraine
Classic Migraine
Chronic Migraine
Other Migraines
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Migraine Headache Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source